[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100521894":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":29,"centralContacts":34,"locations":40,"responsibleParty":57,"collaborators":59,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":10,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":10,"enrollmentInfo":72,"targetDuration":10,"studyType":75,"phases":10,"briefSummary":76,"conditions":77,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"Mayo Clinic","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Observational (Blood and stool sample collection)",null,"Patients undergo blood sample collection throughout the study. Patients also undergo optional stool sample collection and have their medical records reviewed on study. In addition, patients provide previously-collected tissue sample, if available.",[13,14],"Procedure: Biospecimen Collection","Other: Electronic Health Record Review",[16,25],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":21},"PROCEDURE","Biospecimen Collection","Undergo blood and optional stool\u002Ftissue sample collection",[9],[22,23,24],"Biological Sample Collection","Biospecimen Collected","Specimen Collection",{"type":6,"name":26,"description":27,"armGroupLabels":28,"otherNames":10},"Electronic Health Record Review","Medical records are reviewed",[9],[30],{"name":31,"affiliation":32,"role":33},"Svetomir N. Markovic, MD, PhD","Mayo Clinic in Rochester","PRINCIPAL_INVESTIGATOR",[35],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},"Clinical Trials Referral Office","CONTACT","855-776-0015","mayocliniccancerstudies@mayo.edu",[41],{"facility":32,"status":42,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"RECRUITING","Rochester","Minnesota","55905","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-92.4699,44.02163,{"lat":52,"lon":51},[55,56],{"name":36,"role":37,"phone":38,"phoneExt":10,"email":39},{"name":31,"role":33,"phone":10,"phoneExt":10,"email":10},{"type":58,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[60],{"name":61,"class":62},"National Cancer Institute (NCI)","NIH","100521894","evaluation-of-anti-pd-1-therapy-by-monitoring-t-cell-responses-in-melanoma-lung-and-other-cancer-types-100521894",false,"NCT06075524","Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","Maximizing Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types","Inclusion Criteria:\n\n* Are 18 years of age or older\n* Have histologic evidence of locally or regionally advanced or stage IV malignancy\n* Are considered appropriate for starting therapy with anti-PD-1\u002Fanti-PD-L1 monoclonal antibody by their treating physician (prior therapy with immune checkpoint inhibitor (ICI) is allowed)\n* Have an understanding of the protocol and its requirements, risks, and discomforts\n* Are willing to undergo peripheral blood collection at the time points mentioned in the protocol\n* Are able and willing to sign an informed consent\n\nExclusion Criteria:\n\n* Inability on the part of the patient to understand the informed consent or be compliant with the protocol\n* Patients receiving any concurrent anti-cancer therapy or investigational agents (with the exception of an anti-PD-1\u002Fanti-PD-L1 agent as mentioned above)\n* Patients who are pregnant, nursing, or are of childbearing potential and are unwilling to employ adequate contraception","ALL","18 Years",{"count":73,"type":74},500,"ESTIMATED","OBSERVATIONAL","This study explores the role of T cells in monitoring disease status and response during anti-PD-1\u002FPD-L1 treatment in patients with melanoma, lung and other cancer types. Measuring levels of specific targets such as Bim and soluble PD-L1 during therapy may help track treatment resistance and clinical outcomes. This information may also help researchers determine why some people with melanoma, lung and other cancer types respond to PD-1\u002FPD-L1 treatment and others do not.",[78,79,80,81,82,83,84,85,86,87],"Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Locally Advanced Lung Carcinoma","Locally Advanced Malignant Solid Neoplasm","Locally Advanced Melanoma","Metastatic Lung Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Stage III Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","2026-06-16",{"date":90,"type":91},"2026-06-18","ACTUAL",{"date":93,"type":91},"2015-06-15",{"date":95,"type":74},"2028-12-31",{"name":5,"class":6},1]